WuXi Biologics (Cayman) (HKG:2269) said it plans to buy back up to $400 million of its shares from the open market, according to a filing with the Hong Kong bourse.
The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.
The company's shares were up over 4% in recent morning trade.
DL E&C (KRX:375500) disclosed the death of a worker at S-Oil's (KRX: 010950) Shaheen petrochemical project in Ulsan, according to a Tuesday regulatory filing with the Korea Exchange.DL E&C is part of a consortium, alongside Hyundai E&C and Hyundai Engineering, responsible for carrying out the project's core Package One. This phase covers the construction of the site's steam cracker and thermal crude-to-chemicals facilities.The worker's body was discovered seated at the very bottom of a drum at the construction site. Local police and the Ministry of Employment and Labor are expected to conduct an on-site inspection and establish measures to prevent a recurrence, the filing said.Shares of DL E&C and S-Oil rose more than 1% in recent trade.
SSY Group (HKG:2005) obtained registration approval for Safinamide Mesylate to become a bulk drug for the preparations on the market from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is mainly used for the treatment of Parkinson's disease in combination with other Parkinson's drugs such as levodopa, the filing said.
Wasion's (HKG:3393) subsidiary, Wayon Energy, secured new overseas business contracts worth more than 1.6 billion yuan from the start of this year through Tuesday, according to a same-day Hong Kong bourse filing.The contracts mainly cover data center infrastructure and related solutions, as well as overseas power distribution products, including reclosers.